Firms

Audere Capital

New York City, New York, United States · Ridgefield, Connecticut, United States

Audere Capital is a US advanced-technology venture investment firm and innovation platform co-founded by Maggie Sprenger and Peter Ackerson in2023. Its stated strategy connects investment, policy and operating expertise to artificial intelligence, autonomy, defense, healthcare, advanced materials and infrastructure. Its own website identifies Audere Capital LLC; SEC filings independently identify Audere Capital, LLC as manager of Audere Capital SPV11 LLC and the founders as principals of the Delaware Audere Capital FundI LP general partner. Its own company page lists New York City headquarters, while fund filings show a Ridgefield, Connecticut administrative address. The published directory includes two general partners, five venture partners, eight senior advisors, one associate and two venture fellows. AI/healthcare relevance includes Atropos Health’s primary-confirmed September2023 strategic financing, BioPhy clinical-trial/drug-development AI and a published Heimdall genomic-AI portfolio entry. Roles in prior firms and their historical portfolio successes are not automatically Audere investments. This exact audere.capital US firm is distinct from Dubai-regulated Audere Capital Partners Limited and audere-ventures.com. The FundI April2025 amendment reports4.61MUSD sold toward a100MUSD ongoing offering, not a100M closed fund; SPV11 August2025 filing reports first sale yet to occur. Both legal vehicles are recorded without invented final close sizes or dates.

Founded: 2023
Type: Venture capital

Funds2

Audere Capital Fund I, L.P.——
Verified Delaware2023 legal venture fund, CIK1974589. Its April16,2025 amendment reports4.61MUSD actually sold toward a100MUSD ongoing offering, with first sale April17,2024. Final close size/date remain unverified andNULL; first sale is not a final close.
Audere Capital SPV 11 LLC——
Verified Delaware2024 legal venture SPV, CIK2030347, managed by Audere Capital LLC. Its August21,2025 filing reports zero sold and first sale yet to occur. No final close or underlying portfolio allocation independently verified; amount/dateNULL.